Kim Schenk is a panelist on this topic. They will discuss:
•TC Heartland Decision: An Overview
•TC Heartland’s Implications
•Recent Patent Litigation Trends
•Legal and Practical Uncertainties
•Practical Litigation Strategies
CRA is also a sponsor.
For more information on this event, click here.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...